GLUD1 and cancer: The effect of R162 appears to be dependent on GDH1, as demonstrated by another study showing that the combination of R162 and FMK (an inhibitor of the pro-metastatic kinase RSK2) synergistically suppressed invasion and sensitized cancer cells to anoikis, an effect that was abolished in cells lacking GDH1 or RSK2.55